DSpace at RU >

Browsing by Author Ende, M.E. van der

Full Text	Issue Date	Title	Author(s)
	2012	No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial.	Grijsen, M.L.; Steingrover, R.; Wit, F.W.; Jurriaans, S.; Verbon, A., et al
	2012	Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.	Heil, S.G.; Ende, M.E. van der; Schenk, P.W.; Heiden, I. van der; Lindemans, J., et al
	2010	Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.	Luin, M. van; Ende, M.E. van der; Richter, C.; Visser, M. de; Faraj, D., et al
	2009	Efavirenz Dose Reduction Is Safe in Patients With High Plasma Concentrations and May Prevent Efavirenz Discontinuations	Luin, M. van; Gras, L.; Richter, C.; Ende, M.E. van der; Prins, J.M., et al
	2008	Steady-state nevirapine plasma concentrations are influenced by pregnancy.	Nellen, J.F.; Damming, M.; Godfried, M.H.; Boer, K.; Ende, M.E. van der, et al
	2007	Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.	Cleijsen, R.M.; Ende, M.E. van der; Kroon, F.P.; Lunel, F.V.; Koopmans, P.P., et al
	2005	Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modifications.	Porte, C.J.L. la; Schippers, E.F.; Ende, M.E. van der; Koopmans, P.P.; Blok, W.L., et al
	2004	The effect of nevirapine on the pharmacokinetics of indinavir/ritonavir 800/100 mg BID	Burger, D.M.; Prins, J.M.; Ende, M.E. van der; Aarnoutse, R.E.